| Literature DB >> 30608954 |
Chiao-Po Hsu1,2,3, Chun-Yang Huang1,2, Fei-Yi Wu1,2.
Abstract
BACKGROUND: Total arch replacement (TAR) and/or stent graft implantation has been proposed as the primary surgical treatment for acute DeBakey type I aortic dissection. However, the suggestion was based on excellent outcomes of high-volume or aortic centers. How about the real results in most places around the world? The purpose of this study was intended to compared in-hospital mortality, major complications, and aortic remodeling between TAR and/or stent graft implantation in a medical center of northern Taiwan.Entities:
Mesh:
Year: 2019 PMID: 30608954 PMCID: PMC6319728 DOI: 10.1371/journal.pone.0210022
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical and operative characteristics of four surgical groups.
| Clinical Characteristic | I(N = 72) | II(N = 23) | III(N = 45) | IV(N = 16) | P |
|---|---|---|---|---|---|
| Age (years) | 57.9±12.6 | 61.2±11.8 | 57.2±12.8 | 58.8±12.4 | 0.643 |
| Gender(M/F) | 50/22 | 15/8 | 31/14 | 10/6 | 0.942 |
| Hypertension | 60(83.3%) | 20(87.0%) | 32(71.1%) | 11(68.8%) | 0.229 |
| Smoking | 20(27.8%) | 6(26.1%) | 17(37.8%) | 4(25.0%) | 0.611 |
| Coronary artery disease | 11(15.3%) | 0(0) | 7(15.6%) | 2(12.5%) | 0.073 |
| Hyperlipidemia | 3(4.2%) | 1(4.3%) | 3(6.7%) | 1(6.3%) | 0.937 |
| Chronic obstructive pulmonary disease | 5(6.9%) | 3(13.0%) | 1(2.2%) | 1(6.3%) | 0.378 |
| Diabetes mellitus | 8(11.1%) | 3(13.0%) | 6(13.3%) | 1(6.3%) | 0.870 |
| Cerebrovascular accident | 6(8.3%) | 4(17.4%) | 7(15.6%) | 0(0) | 0.112 |
| Previous cardiac surgery | 0(0) | 0(0) | 1(2.2%) | 0(0) | 0.475 |
| Previous aortic surgery | 2(2.8%) | 0(0) | 2(4.4%) | 0(0) | 0.464 |
| Chronic kidney disease | 2(2.8%) | 1(4.3%) | 4(8.9%) | 0(0) | 0.304 |
| Hemodialysis | 0(0) | 0(0) | 2(4.4%) | 0(0) | 0.169 |
| Marfan syndrome | 4(5.6%) | 0(0) | 2(4.4%) | 0(0) | 0.308 |
| Malperfusion | 27(37.5%) | 12(52.2%) | 22(48.9%) | 3(18.8%) | 0.112 |
| IA dissection | 25 (34.7%) | 10 (43.5%) | 24 (53.3%) | 5 (31.3%) | 0.196 |
| LCCA dissection | 22 (30.6%) | 14 (60.9%) | 15 (33.3%) | 6 (37.5%) | 0.066 |
| LSA dissection | 20 (27.8%) | 12 (52.2%) | 13 (28.9%) | 6 (37.5%) | 0.156 |
| Operative Characteristic | |||||
| Brain protection (antegrade/retrograde) | 49/23 | 22/1 | 45/0 | 16/0 | <0.001 |
| Cardiopulmonary bypass(min) | 244.3±52.3 | 336.0±91.1 | 317.6±92.8 | 273.5±58.7 | <0.001 |
| Aortic clamp(min) | 124.8±32.7 | 201.8±52.4 | 166.9±49.3 | 147.5±46.0 | <0.001 |
| Circulatory arrest(min) | 36.0±12.5 | 71.4±22.9 | 53.9±31.4 | 53.6±29.0 | <0.001 |
| Primary tear location | 0.195 | ||||
| Ascending aorta | 41 (56.9%) | 15 (65.2%) | 25 (55.6%) | 9 (56.3%) | |
| Arch (lesser curvature) | 9 (12.5%) | 2 (8.7%) | 5 (11.1%) | 2 (12.5%) | |
| Arch (great curvature) | 4 (5.6%) | 4 (17.4%) | 9 (20.0%) | 3 (18.8%) | |
| Proximal descending aorta | 6 (8.3%) | 1 (4.3%) | 4 (8.9%) | 2 (12.5%) | |
| unknown | 12 (16.7%) | 1 (4.3%) | 2 (4.4%) | 0 (0) | |
| Primary tear resection | 48 (66.7%) | 22 (95.7%) | 37 (82.2%) | 11 (68.8%) | 0.022 |
| Root reconstruction | 15(20.8%) | 7(30.4%) | 3(6.7%) | 3(18.8%) | 0.061 |
| CABG | 1(1.3%) | 1(4.3%) | 0(0) | 0(0) | 0.451 |
| ASA classification (III/IV/V) | 3/60/9 | 1/20/2 | 1/36/8 | 1/14/1 | 0.867 |
ASA: American Society of Anesthesiologists; CABG, Coronary artery bypass graft; IA, innominate artery; LCCA, left common carotid artery; LSA, left subclavian artery; Age, body temperature, cardiopulmonary bypass, aortic clamp, circulatory arrest by T test (normal distribution analysis by Kolmogorov-Smirnov test and Post Hoc test) and other variables by Chi-square test.
* p <0.05 vs. Group I
# p <0.05 vs. Group III.
Postoperative mortality and 30-day morbidity of four groups.
| Operative characteristic | Group I(N = 72) | Group II(N = 23) | Group III(N = 45) | Group IV(N = 16) | P |
|---|---|---|---|---|---|
| Mortality | 13(18.1%) | 9(39.1%) | 12(26.7%) | 1(6.3%) | 0.062 |
| Group I | 0.037 | 0.269 | 0.450 | ||
| Group II | 0.293 | 0.028 | |||
| Group III | 0.153 | ||||
| Stroke | 10(13.9%) | 8(34.8%) | 16(35.6%) | 1(6.3%) | 0.008 |
| Group I | 0.035 | 0.006 | 0.681 | ||
| Group II | 0.950 | 0.056 | |||
| Group III | 0.027 | ||||
| Acute kidney injury | 16(22.2%) | 7(30.4%) | 13(28.9%) | 4(25.0%) | 0.808 |
| Ischemic bowel | 2(2.8%) | 0(0) | 2(4.4%) | 0(0) | 0.464 |
| Re-exploration for bleeding | 7(9.7%) | 2(8.7%) | 8(17.8%) | 0(0) | 0.122 |
| Acute ischemia limb | 2 (2.8%) | 0 | 0 | 0 | 0.373 |
| Respiratory failure | 5 (6.9%) | 5 (21.7%) | 7 (15.6%) | 2 (12.5%) | 0.237 |
| Heart failure | 4 (5.6%) | 1 (4.3%) | 4 (8.9%) | 0 | 0.441 |
| Ischemic colitis | 1 (1.4%) | 0 | 1 (2.2%) | 0 | 0.736 |
| Vocal cord palsy | 1 (1.4%) | 0 | 2 (4.4%) | 0 | 0.432 |
| Hepatic failure | 1 (1.4%) | 1 (4.3%) | 1 (2.2%) | 0 | 0.731 |
| Mediastinitis | 1 (1.4%) | 0 | 2 (4.4%) | 0 | 0.432 |
| Hospital stay | 25.9±33.5 | 39.0±53.9 | 33.8±29.7 | 24.1±17.2 | 0.323 |
* p-value for individual Chi-square test.
Logistic regression analysis for factors associated with in-hospital mortality (N = 156) and surgery-related stroke (N = 120).
| Variables(Number) | n/N(%) | Univariate | P | Multivariate | P |
|---|---|---|---|---|---|
| Crude OR(95%CI) | Adjusted OR(95%CI) | ||||
| Mortality (total 35) | |||||
| Older age(≧65) | 18/47(38.3%) | 3.36(1.54–7.35) | 0.002 | 5.78(1.97–16.99) | 0.001 |
| Malperfusion | |||||
| Cardiac | 14/30(46.7%) | 4.38(1.86–10.31) | 0.001 | 4.28(1.45–12.66) | 0.009 |
| Cerebral | 7/26(26.9%) | 1.34(0.51–3.51) | 0.549 | ||
| Visceral (Liver/intestine) | 8/13(61.5%) | 6.87(2.08–22.67) | 0.002 | 14.02(2.95–66.64) | 0.001 |
| Renal | 3/15(20.0%) | 0.85(0.23–3.20) | 0.812 | ||
| Lower limb | 3/13(23.1%) | 1.04(0.27–4.01) | 0.954 | ||
| Root reconstruction | 10/28(35.7%) | 2.29(0.94–5.56) | 0.068 | 3.85(1.22–12.15) | 0.021 |
| Total arch replacement | 21/68(30.9%) | 2.36(1.10–5.09) | 0.028 | 3.31(1.22–8.99) | 0.019 |
| Descending aorta stent grafting | 13/61(21.0%) | 0.90(0.41–1.95) | 0.787 | ||
| Surgical groups | |||||
| I | 13/72(18.1%) | reference | |||
| II | 9/23(39.1%) | 2.92(1.04–8.18) | 0.042 | ||
| III | 12/45(26.7%) | 1.65(0.68–4.03) | 0.271 | ||
| IV | 1/16(6.3%) | 0.30(0.04–2.50) | 0.267 | ||
| Surgery-related stroke (total 15) | |||||
| Older age(≧65) | 6/35(17.1%) | 1.75(0.57–5.34) | 0.328 | ||
| Root reconstruction | 0/21(0%) | - | - | ||
| Total arch replacement | 12/48(25.0%) | 7.67(2.03–28.92) | 0.003 | 7.81(1.77–34.47) | 0.007 |
| Descending aorta stent grafting | 9/48(18.8%) | 2.54(0.84–7.67) | 0.099 | 0.97(0.27–3.50) | 0.956 |
| Surgical groups | |||||
| I | 3/58(5.2%) | reference | |||
| II | 3/14(21.4%) | 5.0(0.89–28.10) | 0.068 | ||
| III | 9/34(26.5%) | 6.6(1.65–26.49) | 0.008 | ||
| IV | 0/14(0%) | 0(0) | 0.999 | ||
# Not included in multivariate model; CI: confidence intervals; OR: odds ratio.
Logistic regression analysis for factors associated with patent false lumen after one year (N = 95).
| Variables (Number) | n/N (%) | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| Crude OR(95%CI) | p | Adjusted OR(95%CI) | p | ||
| Patent false lumen (total 50) | |||||
| Tear resection | 32/68(47.1%) | 0.44(0.18–1.13) | 0.088 | ||
| Root reconstruction | 11/16(68.8%) | 2.26(0.72–7.09) | 0.164 | ||
| Total arch replacement | 8/32(25.0%) | 0.17(0.06–0.43) | 0.000 | 0.31(0.10–0.94) | 0.038 |
| Descending aorta stent grafting | 7/37(18.9%) | 0.08(0.03–0.22) | 0.000 | 0.11(0.04–0.32) | 0.000 |
| Surgical groups | |||||
| I | 37/48(77.1%) | reference | |||
| II | 6/10(60.0%) | 0.45(0.11–1.87) | 0.269 | ||
| III | 2/22(9.1%) | 0.03(0.01–0.15) | 0.000 | ||
| IV | 5/15(33.3%) | 0.15(0.04–0.53) | 0.003 | ||
# Not included in multivariate model; CI: confidence intervals; OR: odds ratio
Fig 1Volumetric change ratio of true (DsAo TL) and false (DsAo FL) lumen of descending aortic segment at one-year postoperative in four surgical groups.
Box plots show median and interquartile ranges of remodeling ratios. Group I: proximal aortic replacement (PAR) only; Group II: concomitant total arch replacement (TAR); Group III: concomitant TAR extending with stent graft; Group IV: PAR with descending aorta stent grafting.